Survival Up 2.6 Months, AACR Is the Next Catalyst Amplia Therapeutics released results from its ACCENT Phase 1b trial, sending the share price up 80%. The key number was median overall survival, which improved by 2.6 months from the standard 8.5 months. That matters because NALIRIFOX was approved by the FDA based on a median overall…

4 out of 5 oil shocks lead to a recession The ASX has fallen 7.6% since hitting a record high on 2 March and is now moving closer to correction territory. JPMorgan became the first major bank to cut its S&P 500 target, warning that investors are still too complacent. Its strategy team pointed out…

Third Patient Dosed, No Toxicity, Dose Escalation Next Race Oncology(ASX: RAC) rose 21% after successfully dosing its third patient with RC220 in the CPACS study for anti-cancer synergy. This took place in the company’s Phase 1 trial at Queen Mary Hospital in Hong Kong. The patient received a 40mg/m² dose, with no side effects reported. Importantly, no…